95 Participants Needed

Digital CBT for Anxiety in Cardiovascular Disease Patients

MP
Overseen ByMarie Parsons, Ph.D.
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Boston University Charles River Campus
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

The treatment of generalized anxiety disorder (GAD) in an accessible manner represents an unmet need for those with cardiovascular disease (CVD), given that patients with CVD experience numerous barriers for in-person treatment engagement. The research plan for the proposed pilot project will entail: (1) open study of the acceptability of the digital intervention (N=5), followed by (2) recruitment and randomization of 90 individuals with a history of acute CVD events and clinical levels of GAD symptoms to dCBT or a waitlist (Control) condition, using a 1.5:1 allocation (dCBT:Control).

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications. However, if you have started or changed the dosage of any psychotropic medications (medications that affect your mood, thoughts, or behavior) in the past 4 weeks, you may not be eligible to participate.

What data supports the effectiveness of the treatment Daylight dCBT Application for anxiety in cardiovascular disease patients?

Research shows that digital cognitive behavioral therapy (dCBT) can help reduce anxiety and worry in patients with cardiovascular disease, which may improve their overall heart health. Additionally, digital CBT has been effective in reducing symptoms of anxiety and depression in other health conditions, suggesting it could be beneficial for cardiovascular patients as well.12345

Is digital cognitive behavioral therapy (dCBT) safe for humans?

Digital cognitive behavioral therapy (dCBT) has been used for over a decade and is generally considered safe for humans, with studies showing it as an acceptable treatment for conditions like insomnia, depression, and anxiety in various populations.15678

How is the Daylight dCBT Application treatment different from other treatments for anxiety in cardiovascular disease patients?

The Daylight dCBT Application is unique because it offers a digital, scalable, and affordable way to address anxiety in cardiovascular disease patients, who often face barriers to in-person therapy. Unlike traditional treatments, this digital cognitive behavioral therapy (dCBT) can be accessed remotely, making it more accessible and convenient for patients.12349

Eligibility Criteria

This trial is for adults over 18 who've had a recent acute cardiovascular event like a heart attack or stroke and are experiencing anxiety. They must be past the initial recovery phase, which means at least 2 months since their cardiac event, and have clinical levels of generalized anxiety.

Inclusion Criteria

Age 18 or older.
Experienced an acute CVD event (i.e., myocardial infarction, stroke/transient ischemic attack, cardiac arrest, unstable angina, congestive heart failure with hospitalization; exclusion of coronary heart disease, atrial fibrillation, and other arrhythmias)
Clinical levels of GAD symptoms as operationalized by a score of ≥10 on the GAD-7
See 1 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Open Study

Open study of the acceptability of the digital intervention with a small group of participants

3 weeks
1 visit (virtual)

Treatment

Participants are randomized to receive digital CBT or placed on a waitlist control condition

10 weeks
4 assessments (virtual) at Week 0, Week 3, Week 6, and Week 10

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • Daylight dCBT Application
Trial Overview The study is testing a digital Cognitive Behavioral Therapy (dCBT) app called Daylight to see if it helps people with heart disease manage anxiety and improve health behaviors. Participants will either use the dCBT app or be put on a waitlist as part of the control group.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: Digital Cognitive Behavior Therapy (dCBT) for Generalized Anxiety DisorderExperimental Treatment1 Intervention
Group II: Waitlist ControlActive Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Boston University Charles River Campus

Lead Sponsor

Trials
125
Recruited
14,100+

Findings from Research

The internet-based cognitive behavior therapy (iCBT) program significantly reduced symptoms of distress disorder in cardiovascular disease (CVD) patients compared to an online discussion forum, with improvements noted at both 6- and 12-month follow-ups.
While the iCBT program also helped reduce avoidance behaviors related to fear disorder, it was less effective for other fear symptoms, indicating that the program primarily targeted distress rather than fear-related issues.
The effects of internet-based cognitive behavior therapy for depression in cardiovascular disease on symptoms of anxiety: A secondary analysis of a randomized trial.Westas, M., Mourad, G., Andersson, G., et al.[2023]
This study proposes a digital cognitive behavior therapy (dCBT) intervention aimed at treating generalized anxiety disorder (GAD) in patients who have experienced acute cardiovascular disease (CVD), addressing a significant barrier to in-person treatment.
The randomized clinical trial will assess the effectiveness of dCBT in reducing GAD symptoms and improving cardiac health behaviors in 90 adults, potentially enhancing overall care for CVD patients by targeting anxiety without straining existing medical resources.
Initial assessment of the feasibility and efficacy of a scalable digital CBT for generalized anxiety and associated health behaviors in a cardiovascular disease population.Parsons, EM., Hiserodt, M., Otto, MW.[2023]
A digital mental health program providing internet-based cognitive behavioral therapy (iCBT) was successfully implemented in primary care, with 2,228 patients prescribed the program and nearly 49% enrolling, indicating good acceptance among patients.
Patients who engaged with the iCBT program showed significant clinical improvements, with a 23% reduction in depression scores (PHQ-9) and a 26% reduction in anxiety scores (GAD-7), demonstrating the efficacy of digital tools in treating mental health conditions.
Addressing depression and behavioral health needs through a digital program at scale.Sharif-Sidi, Z., Shen, C., Wong, W., et al.[2021]

References

The effects of internet-based cognitive behavior therapy for depression in cardiovascular disease on symptoms of anxiety: A secondary analysis of a randomized trial. [2023]
Initial assessment of the feasibility and efficacy of a scalable digital CBT for generalized anxiety and associated health behaviors in a cardiovascular disease population. [2023]
Addressing depression and behavioral health needs through a digital program at scale. [2021]
Lessons learned from an attempted randomized-controlled feasibility trial on "WIDeCAD" - An internet-based depression treatment for people living with coronary artery disease (CAD). [2023]
Digital Delivery of Cognitive Behavioral Therapy for Insomnia. [2020]
Tips and Traps: Lessons From Codesigning a Clinician E-Monitoring Tool for Computerized Cognitive Behavioral Therapy. [2020]
Patient Experiences of Web-Based Cognitive Behavioral Therapy for Heart Failure and Depression: Qualitative Study. [2022]
Rapid Evidence Review of Digital Cognitive-Behavioral Therapy for Adolescents With Depression. [2022]
Trajectories and associations between depression and physical activity in patients with cardiovascular disease during participation in an internet-based cognitive behavioural therapy programme. [2021]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security